MAM
GNCA

Meeder Asset Management’s Genocea Biosciences, Inc. GNCA Stock Holding History

Meeder Asset Management’s Portfolio GNCA Stock Details GNCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-330
Closed -$2.26K – 1780
2018
Q2 		$2.26K Hold
330
– – ﹤0.01% 1402
2018
Q1 		$3K Buy
330
+121
+58% +$1K ﹤0.01% 1352
2017
Q4 		$2K Buy
+209
New +$2.1K ﹤0.01% 1536

Other funds holding GNCA

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
FI
Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Meeder Asset Management's GNCA Position: Q3 2018 in Review

Meeder Asset Management sold out of Genocea Biosciences, Inc. (GNCA) in Q3 2018, closing a stake of 330 shares — an estimated $2.26K sold.

Meeder Asset Management first reported a position in GNCA in Q4 2017 and held it in 3 quarters. The position peaked at $3K in Q1 2018. 48 funds tracked by Wall St. Rank hold GNCA as of Q3 2018.

  • Meeder Asset Management reported no remaining Genocea Biosciences, Inc. position as of Q3 2018 after selling out during the quarter.
  • Meeder Asset Management sold 330 Genocea Biosciences, Inc. shares in Q3 2018, an estimated $2.26K.
  • Meeder Asset Management first reported a position in Genocea Biosciences, Inc. in Q4 2017 and held it in 3 quarters.
  • Meeder Asset Management's Genocea Biosciences, Inc. position peaked at $3K in Q1 2018.
  • 48 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q3 2018.

Based on Meeder Asset Management's 13F filing for Q3 2018, filed 2 Nov 2018.